Novel emerging biomarkers to immunotherapy in kidney cancer
The treatment of metastatic renal cell carcinoma has significantly evolved in recent years, particularly with the advent of novel immune checkpoint inhibitors (ICI). Despite the striking benefits observed on a population level, outcomes vary and some patients do not respond to ICI-based regimens, ul...
Guardado en:
Autores principales: | Yasser Ged, Martin H. Voss |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
SAGE Publishing
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/85f04da038e547b387181e4738d986d2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies
por: Andrew Wallace, et al.
Publicado: (2021) -
Cancer immunology and immunotherapy
por: Xiubao Ren
Publicado: (2021) -
Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
por: Hong-fen Guo, et al.
Publicado: (2021) -
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
por: Amaia Lujambio, et al.
Publicado: (2021) -
Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
por: Chuan HUANG, et al.
Publicado: (2021)